Cognition Therapeutics schedules FDA meeting to align on Phase 3 DLB trial endpoints
CGTX•Cognition Therapeutics scheduled an FDA Type C meeting for October 20, 2026, to align on the primary endpoint for a Phase 3 trial of zervimesine (CT1812) in DLB.
1. FDA meeting scheduled
Cognition Therapeutics scheduled a Type C meeting with the FDA for October 20, 2026, to align on the primary endpoint for a Phase 3 study of zervimesine (CT1812) in DLB.
